For a child on day three of oral prednisolone for an asthma exacerbation who missed a scheduled albuterol (levosalbutamol) nebulisation dose, with SpO₂ 98%, heart rate 86 bpm, normal respiratory rate, no retractions or breathlessness but wheeze on auscultation, what is the appropriate management?

Management Recommendation

Continue oral prednisolone as prescribed, administer the missed levosalbutamol nebulization dose now (0.31 mg), and continue scheduled nebulizations every 12 hours until symptoms fully resolve, with close monitoring for clinical deterioration. 12

Clinical Assessment

This child is on day 3 of an asthma exacerbation treatment course and presents with:

• Reassuring vital signs: SpO₂ 98%, HR 86 bpm, normal respiratory rate, no retractions, no breathlessness
• Persistent airway inflammation: Wheeze audible on auscultation despite clinical stability

The presence of wheeze indicates ongoing bronchospasm and airway inflammation, even though the child appears clinically stable. This is a critical window where inadequate treatment can lead to relapse or progression.

Immediate Management

Bronchodilator Therapy

Administer the missed levosalbutamol dose immediately (0.31 mg nebulization). The NAEPP guidelines specify that during acute exacerbations, children should receive 0.15 mg/kg (minimum 1.25 mg for levalbuterol) every 1-4 hours as needed after the initial intensive phase 1. Your dose of 0.31 mg appears lower than guideline recommendations—verify the child's weight and consider if dose adjustment is needed.

• The child missed only one morning dose and is clinically stable, so there's no need for intensive every-20-minute dosing
• Continue the scheduled twice-daily regimen until wheeze resolves completely
• Levosalbutamol (the R-isomer) provides comparable efficacy to racemic salbutamol at half the dose with less tachycardia and fewer electrolyte disturbances 34

Corticosteroid Therapy

Continue oral prednisolone at 1-2 mg/kg/day (maximum 60 mg/day) until clinical resolution. The FDA label and guidelines support 3-10 days of treatment, with most children requiring the full course 2. The presence of persistent wheeze on day 3 indicates:

• Ongoing airway inflammation requiring continued anti-inflammatory therapy
• The typical 3-day course may be insufficient for this child
• Consider extending to 5-7 days if wheeze persists beyond day 5

Recent evidence shows 1 mg/kg/day prednisolone is non-inferior to 2 mg/kg/day for moderate exacerbations and causes less vomiting 5, but if this child is on the higher dose, continue it given the persistent wheeze.

Monitoring Parameters

Reassess the child within 24-48 hours for:

• Resolution of wheeze on auscultation (most important indicator)
• Respiratory rate, work of breathing, oxygen saturation at rest
• Ability to perform normal activities without symptoms
• Nocturnal symptoms or early morning wheeze

Red Flags Requiring Escalation

Return immediately or escalate therapy if:

• Increased work of breathing, retractions, or accessory muscle use develops
• SpO₂ drops below 92%
• Respiratory rate increases significantly from baseline
• Poor response to nebulization within 1 hour
• Inability to speak in full sentences or feed normally

Duration of Therapy

Do not stop bronchodilators prematurely. The guideline-recommended approach is to continue treatment until:

• Complete resolution of wheeze on auscultation
• Normal activity tolerance without symptoms
• Typically 5-7 days total for moderate exacerbations 12

The child is only on day 3, and persistent wheeze indicates the exacerbation has not fully resolved. Premature discontinuation risks relapse within days.

Common Pitfalls to Avoid

1. Stopping treatment based solely on normal vital signs: SpO₂ and respiratory rate can be normal while significant bronchospasm persists (as in this case with audible wheeze)

2. Inadequate corticosteroid duration: The 3-day rule is a minimum; many children need 5-10 days 2. Persistent wheeze on day 3 suggests longer treatment is needed

3. Missing doses of bronchodilators: Even one missed dose can allow bronchospasm to worsen, particularly in the morning when airway inflammation is typically worse

4. Premature weaning: Unlike maintenance therapy, burst corticosteroid therapy for exacerbations does not require tapering 2, but it must continue until clinical resolution

Transition to Maintenance Therapy

Once the exacerbation fully resolves:

• Reassess the child's baseline asthma control and maintenance therapy
• If this represents poor control on current maintenance therapy, step up the maintenance regimen
• Ensure proper inhaler technique and adherence
• Provide an asthma action plan for future exacerbations

The presence of wheeze on day 3 despite treatment suggests either inadequate initial therapy intensity or more severe inflammation than initially appreciated. Close follow-up is essential.